We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
201
Regenxbio
RGNX
$521M
$589K 0.14%
49,129
+29,469
+150% +$245K
OCSL icon
202
Oaktree Specialty Lending
OCSL
$1.1B
$559K 0.13%
46,824
-17,758
-27% -$214K
QURE icon
203
uniQure
QURE
$2.96B
$547K 0.13%
11,867
-2,110
-15% -$55.2K
VVR icon
204
Invesco Senior Income Trust
VVR
$446M
$530K 0.12%
176,549
-26,624
-13% -$81.4K
SCM icon
205
Stellus Capital Investment Corp
SCM
$225M
$523K 0.12%
62,135
+1,463
+2% +$13.4K
SPMC
206
Sound Point Meridian Capital
SPMC
$191M
$520K 0.12%
52,537
-14,605
-22% -$153K
CCAP icon
207
Crescent Capital BDC
CCAP
$363M
$520K 0.12%
47,621
+2,703
+6% +$33K
MBX
208
MBX Biosciences
MBX
$2.94B
$509K 0.12%
9,215
+84
+0.9% +$2.93K
MNPR icon
209
Monopar Therapeutics
MNPR
$702M
$507K 0.12%
5,474
+1,819
+50% +$113K
CGBD icon
210
Carlyle Secured Lending
CGBD
$788M
$493K 0.11%
46,857
-8,866
-16% -$98.8K
FDMT icon
211
4D Molecular Therapeutics
FDMT
$769M
$493K 0.11%
37,055
+11,901
+47% +$116K
APGE
212
DELISTED
Apogee Therapeutics
APGE
$492K 0.11%
3,705
+167
+5% +$15K
ABCL icon
213
AbCellera Biologics
ABCL
$3.78B
$490K 0.11%
62,442
-12,885
-17% -$63K
NMFC icon
214
New Mountain Finance
NMFC
$662M
$482K 0.11%
67,254
-22,217
-25% -$177K
AKTS
215
Aktis Oncology
AKTS
$1.22B
$481K 0.11%
+14,920
New +$306K
FSCO
216
FS Credit Opportunities Corp
FSCO
$1.07B
$479K 0.11%
96,005
+4,128
+4% +$20.7K
JBIO
217
Jade Biosciences
JBIO
$1.08B
$474K 0.11%
21,329
+3,126
+17% +$65.2K
NRIX icon
218
Nurix Therapeutics
NRIX
$2.61B
$468K 0.11%
19,304
+5,005
+35% +$85.3K
SAR icon
219
Saratoga Investment
SAR
$280M
$463K 0.11%
20,757
-4,995
-19% -$112K
MGTX icon
220
MeiraGTx Holdings
MGTX
$1.24B
$461K 0.11%
34,119
+3,549
+12% +$35.3K
PVLA
221
Palvella Therapeutics
PVLA
$2.21B
$460K 0.11%
3,007
+242
+9% +$29.4K
SLDB icon
222
Solid Biosciences
SLDB
$912M
$458K 0.11%
+45,826
New +$347K
NTLA icon
223
Intellia Therapeutics
NTLA
$1.63B
$457K 0.11%
27,019
-3,211
-11% -$44.9K
BCAX
224
Bicara Therapeutics
BCAX
$1.49B
$448K 0.1%
15,086
+331
+2% +$7.39K
GENB
225
Generate Biomedicines
GENB
$2.07B
$446K 0.1%
+26,430
New +$360K
7 8
9
10 11

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.